Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia
SM Hoy - Drugs, 2014 - Springer
Oral ponatinib (Iclusig®) is a novel kinase inhibitor structurally designed with a carbon-
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
SM Hoy - Drugs, 2014 - infona.pl
Oral ponatinib (Iclusig®) is a novel kinase inhibitor structurally designed with a carbon-
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia.
SM Hoy - Drugs, 2014 - europepmc.org
Oral ponatinib (Iclusig (®)) is a novel kinase inhibitor structurally designed with a carbon-
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia.
S Hoy - Drugs, 2014 - search.ebscohost.com
Oral ponatinib (Iclusig) is a novel kinase inhibitor structurally designed with a carbon-carbon
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
[引用][C] Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
SM Hoy - Drugs, 2014 - cir.nii.ac.jp
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia
Chromosome-Positive Acute Lymphoblastic Leukaemia | CiNii Research CiNii 国立情報学 …
Chromosome-Positive Acute Lymphoblastic Leukaemia | CiNii Research CiNii 国立情報学 …
[引用][C] Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
SM HOY - Drugs (Basel), 2014 - pascal-francis.inist.fr
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia
Chromosome-Positive Acute Lymphoblastic Leukaemia CNRS Inist Pascal-Francis CNRS …
Chromosome-Positive Acute Lymphoblastic Leukaemia CNRS Inist Pascal-Francis CNRS …
Ponatinib: a review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia
SM Hoy - Drugs, 2014 - pubmed.ncbi.nlm.nih.gov
Oral ponatinib (Iclusig (®)) is a novel kinase inhibitor structurally designed with a carbon-
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
carbon triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia
SM Hoy - Drugs, 2014 - search.proquest.com
Oral ponatinib (Iclusig) is a novel kinase inhibitor structurally designed with a carbon-carbon
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
Ponatinib: A Review of Its Use in Adults with Chronic Myeloid Leukaemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia.
S Hoy - Drugs, 2014 - search.ebscohost.com
Oral ponatinib (Iclusig) is a novel kinase inhibitor structurally designed with a carbon-carbon
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …
triple bond to accommodate the T315I mutation in the ABL kinase domain. It has …